Inventiva’s 2021 First-Half Financial Results Presentation
10 Septiembre 2021 - 8:00AM
Inventiva’s 2021 First-Half Financial Results Presentation
Daix (France), September 10, 2021 – Inventiva (Euronext
Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company
focused on the development of oral small molecule therapies for the
treatment of non-alcoholic steatohepatitis (NASH),
mucopolysaccharidoses (MPS) and other diseases with significant
unmet medical need, today announced that its management team will
host a webcast to present the Company’s first-half financial
results for 2021 on Tuesday, September 21, 2021.
Inventiva’s 2021
first-half financial results will be released on Monday,
September 20, 2021 at 4:00 pm (New York), 10:00 pm (Paris).
Frédéric Cren, Chairman, CEO and cofounder of
Inventiva and Jean Volatier, Chief Financial Officer of Inventiva,
will hold a conference call in English, followed by a
Q&A session, on Tuesday, September 21, 2021 at 8:00
am (New York), 2:00 pm (Paris).
The conference call and the slides of the
presentation will be webcast live at:
https://edge.media-server.com/mmc/p/2kk6k5k7. They will also be
available on Inventiva’s website in the “Investors” – “Financial
results” section.
To join the conference call, please use the code
8573858 after dialing one of the following numbers:
France: +33 1 70 70 07 81
Belgium: +32 27 93 38 47 Germany: +49 69 22 22
26 25Netherlands: +31 20 79 56 614Switzerland: +41 44 58 07
145United Kingdom: +44 207 19 28 338
United States: +1 646-741-3167
Please note that the line will be opened 10 minutes before the
start of the conference call.
A replay of the conference call and the
presentation will be available after the event at:
http://inventivapharma.com/investors/financial-results-presentations/.
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of earlier
stage programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. Inventiva recently announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
Breakthrough Therapy and Fast Track designation for lanifibranor in
the treatment of NASH.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients at the end of
2019 and received FDA Fast Track designation in MPS VI for
odiparcil in October 2020.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com
Contacts
InventivaPascaline ClercVP of Global External Affairs
media@inventivapharma.com+1 240 620 9175 |
Brunswick GroupYannick Tetzlaff / Tristan Roquet Montegon /
Aude LepreuxMedia relationsinventiva@brunswickgroup.com+33 1 53 96
83 83 |
Westwicke, an
ICR CompanyPatricia L. Bank Investor
relationsPatti.bank@westwicke.com+1 415 513 1284 |
- Inventiva - PR - EN - Webcast invitation H1 2021 - 09 10
2021
Inventiva (LSE:0RNK)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Inventiva (LSE:0RNK)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024